|
|
Roger
S. Day, ScD
Research Associate Professor,
Biostatistics &
Center for Biomedical Informatics
Education
BA, Wesleyan
University, 1972
MA, Wesleyan University,
1981
ScD, Harvard University, 1984
Research Fellowship, National Institute for Environmental Health
Sciences, 1986
Research Interests
I lead the Educational
Resource for Tumor Heterogeneity, and continue the evolution
of the Oncology Thinking
Cap computer modeling facility, which uses stochastic models
of tumor growth to help cancer researchers do thought experiments
about cancer biology and treatment, and to help cancer educators
develop their abilities to reason across the bridge from basic cancer
science through implications for patients and clinical trials.
We also develop knowledge management tools to help support a systematic
process of model-building and validation. This work is only
possible because of the strong contributions and support of a great
team.
I work with Stan
Shackney to understand how disease-free survival curves can be used
to shed light on the contentious dosing issues in adjuvant breast
cancer treatment. We also work on the genetic evolution of
breast cancers, through molecular studies of individual cells in
tumor cell samples, and through modeling. Our long-range goal
is to radically improve our ability to predict response of individual
patients to a variety of cancer therapies and strategies.
Together with my
student Thomas Richards, I am developing "weakest link"
statistical models that reflect more realistically the kinds of
relationships that exist in the real world, especially in biology
and medicine. We have found examples throughout cancer research
of "interactions without main effects", and have developed
methods for detecting them that are practical and more effective
than the usual linear modeling. (Health
Sciences Faculty Research Interests Project)
Courses
BIOST 2018: Statistical Foundations for Bioinformatics Data Mining
BIOST 2062: Clinical Trials: Methods and Practice
BIOST 2063: Bayesian and Empirical Bayes Statistical Methods
BIOST 2064: Bayesian and Empirical Bayes Computational Methods
MED 5175: Neoplasia and Neoplastic Disease
Statistics of cancer clinical trials; computer-base workshop on clinical trials using OncoTCap V3
Selected Publications
"Challenges of Biological Realism and Validation in
Simulation-Based Medical Education." Day RS. Artificial Intelligence in Medicine.
In press. 2005.
"The analysis of relapse-free survival
curves: implications for evaluating intensive systemic adjuvant
treatment regimens for breast cancer." Day RS, Shackney SE, Peters WP. British Journal of Cancer. Br J
Cancer. 2005 Jan 17;92(1):47-54.
"Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer." Ramanathan RK, Lee K, Mckolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborn J, Kim H, Day RS, Troetchel M, Finn OJ. Cancer Immunology and Immunotherapy. Epub, September 14, 2004. "Evaluation of the OncoTCap (Oncology Thinking Cap) Simulation in Teaching Medical Students about Clinical Trials: Some Successes and Some Surprises." Day RS, Manning BK, Garrott D, Brufsky AM, Baar J, Egorin MJ, Shirey WE, Friedman C. J Cancer Ed. 19(3):149-155, 2004.
"The low over-expression of HER-2/neu in Advanced Colo-Rectal Cancer limits the usefulness of Trastuzumab (Herceptin®) and Irinotecan as therapy. A Phase II trial." Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, Earle M, Brufsky A, Evans T, Troetschel M, Walko C, Day R, Chen HX, Finkelstein S. Cancer Invest. 22(6):858-865, 2004.
"Intracellular Patterns of Her-2/neu, ras, and Ploidy Abnormalities in Primary Human Breast Cancers Predict Postoperative Clinical Disease Free Survival". Stanley E. Shackney, Charles A. Smith, Agnese Pollice, Kathryn Brown, Roger Day, Thomas Julian, and Jan F. Silverman. Clinical Cancer Research. May 1;10(9):3042-52. 2004.
"Phase II Study of Topotecan and Paclitaxel for Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer". Ramalingam S, Belani CP, Day RS, Jacobs SA, Jett JR. Annals of Oncology. Feb;15(2):247-51. 2004.
"Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines." Carey Welsh, Roger Day, Claire McGurk, John R. W. Masters, Richard D. Wood and Beate Köberle. Int. J Cancer. Jun 20;110(3):352-61. 2004.
"Modeling Cellular Processes with Variational Bayesian Cooperative Vector Quantizer <http://www-smi.stanford.edu/projects/helix/psb04/lu.pdf>". Lu X, Hauskrecht M, Day RS. Proceedings of the Pacific Symposium on Biocomputing. 533-544, January 2004.
"Weakest Link Models for Detecting Small Groups of Genes to Predict Lung Cancer Survival, CAMDA'03 (Critical Assessment of Microarray Data Analysis", Richards TJ, Day RS, Kaminski N. Durham, North Carolina, November 2003.
"Phase I and Pharmacokinetics study of vinblastine and high dose megestrol acetate." Matin K, Egorin MJ, Bellesteros MF, Smith DC, Lembersky B, Day RS, Johnson CS, Trump DL. Cancer Chemother Pharmacol. 50(3):179-85, 2002.
"Detection of EBV genomes in peripheral blood B cells from solid organ transplant recipients by fluorescent in situ hybridization." Rose C, Green M, Webber S, Kingsley L, Day R, Watkins S, Reyes J, Rowe D. J Clin Microbiol. 40(7):2533-44, 2002.
"Integration of a Cancer
Research KnowledgeBase with a Cross-Hierarchy Modeling Platform."
Day RS, Shirey WE. Proceedings of the 2nd International
Conference on Systems Biology, Pasadena, California, Nov
5-7, 2001.
"It's harder
than we thought it would be: A comparative case study of expert-novice experimentation strategies." Hmelo CE, Nagarajan
A, and Day RS. Science Education, in press, 2001.
"The number
of intratumoral dendritic cells and zeta-chain expression in T cells
as prognostic and survival biomarkers in patients with oral carcinoma."
Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL.
Cancer, 91(11):2136-47, 2001.
"The Oncology
Thinking Cap: Scaffolded use of a simulation to learn clinical
trial design." Hmelo CE, Ramakrishnan, Day RS, Shirey WE, Brufsky A,
Johnson C, Baar J, Huang,Q.
Teaching and Learning in Medicine, 13(3), 2001.
"Analysis
of therapeutic and immunologic effects of R-24 anti-GD# monoclonal
antibody in 37 patients with metastatic melanoma." Kirkwood
JM, Mascari RA, Edington HD, Rabkin MS, Day RS, Whiteside TL, Vlock
DR, Shipe-Spotloe JM. Cancer, 88(12):2693-2702, 2000.
"Detection
of bladder cancer using a novel matrix protein, BLCA-4." Konety
BR, Nguyen TST, Dhir R, Day RS, Becich MJ, Stadler WM, Getzenberg
RH. Clin Cancer Res. 6, 2618-2625, 2000.
"Evidence
that anoreceptive intercourse with ejaculate exposure is associated
with rapid CD4 cell loss." Wiley DJ, Visscher BR, Grosser S,
Hoover DR, Day R, Gange S, Chmiel JS, Mitsuyasu R, Detels R.
AIDS, (6) 707-715, 2000.
"Effects of
high and low prior knowledge on construction of a joint problem
space." Hmelo CE, Nagarajan A, and Day RS. Journal of Experimental
Education, 69, 36-56, 2000.
"Pharmacokinetic
and pharmacodynamic study of the combination of docetaxel and topotecan
in patients with solid tumors." Zamboni WC, Egorin MJ, Van
Echo DA, Day RS, Meisenberg BR, Brooks SE, Doyle LA, Nemieboka NN,
Dobson JM, Tait NS, Tkaczuk KH. Journal of Clinical Oncology,
18(18):3288-3294, 2000.
"Commentary
on Lee & Zelen 'Clinical Trials and Sample Size Considerations:
Another Perspective'." Bryant JL, Day RS. Statistical
Science, 15:106-108, 2000.
"Brain tumor
volume measurement: comparison
of manual and semiautomated methods." Joe BN, Fukui MB, Meltzer
CC, Huang Q, Day RS, Greer PJ, Bozik ME.
Radiology, 212(3):811-816, 1999.
"Contextualized
Questioning to Scaffold Learning From Simulations." Hmelo C
and Day R. Computers & Education, 32:151-164,
1999.
"Paclitaxel
and carboplatin with simultaneous thoracic irradiation in regionally
advanced non-small cell lung cancer." Belani CP, Aisner J,
Ramanathan R, Jett J, Greenberger J, Day R, Capazolli MJ, Hiponia
D, Engstrom C. Seminars in Radiation Oncology, 7(2):S1-S11-S13-S-14,
1999.
"Efficacy
of Cisplatin, 5-Fluorouracil, and Paclitaxel Regimen for Carcinoma
of the Esophagus." Belani CP, Luketich JD, Landreneau RJ, Kim
R, Ramanathan RK, Day R, Ferson PF, Keenan RJ, Posner M, Seger J,
Lembersky B. Seminars in Oncology, 1998.
"All-trans-retinoic
acid modulation of drug-metabolizing enzyme activities: investigation
with selective metabolic drug probes." Adedoyin A, Stiff DD,
Smith DC, Romkes M, Bahnson RC, Day R, Hofacker J, Branch RA, Trump
DL. Cancer Chemotherapy & Pharmacology, 41:133-139,
1998.
"Tumor biology
modeling workbench for prospectively evaluating cancer treatments."
Day R, Shirey W, Ramakrishnan S, Huang Q. Proceedings of
the CESA '98 IMACS Multiconference. April 1998.
"Absent or
Low Expression of the Zeta Chain in T Cells at the Tumor Site Correlates
with Poor Survival in Patients with Oral Carcinoma." Reichert
TE, Day RS, Wagner EM, Whiteside TL. Cancer Research,
58(23);5344-5347, 1998.
"Tumor Levels
of TGF-and EGFR Protein Predict Survival in Patients with Head and
Neck Squamous Cell Carcinoma." Grandis JR, Melhem MF, Gooding
WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ.
Journal of the National Cancer Institute, 90(11):824-832,
1998.
"Lymphatic
Mapping with Isoulfan Blue Dye in Head and Neck Squamous Cell Carcinoma."
Pitman KT, Johnson JT, Edington H, Barnes EL, Day R, Wagner RL,
Myers EN. Archives of Ontolaryngology and Head and Neck
Surgery, 124(7):790-793, 1998.
"A phase II
trial of all-trans-retinoic acid in hormone-refractory prostate
cancer: a clinical trial with detailed pharmacokinetic analysis."
Trump DL. Smith DC. Stiff D. Adedoyin A. Day R. Bahnson RR. Hofacker
J. Branch RA. Cancer Chemotherapy & Pharmacology, 39(4):349-56,
1997.
"Efficacy
of Cisplatin, 5-Fluorouracil, and Paclitaxel Regimen for Carcinoma
of the Esophagus." Belani CP, Luketich JD, Landreneau RJ, Kim
R, Ramanathan RK, Day R, Ferson PF, Keenan RJ, Posner M, Seger J,
Lembersky B.Seminars in Oncology, 24(6):S19-89-S19-92, 1997.
"Adapting
Bivariate Frailty Models for Prediction with Application to Biological
Markers as Prognostic Factors." Day R, Bryant J, Lefkopoulou
M. Biometrika, 84:1, pp. 45-56, 1997.
"On the Rate
of Convergence of the ECME for Multiple Regression Models with t-distributed
Errors." Kowalski J, Tu XM, Day R, Mendoza-Blanco JR. Biometrika,
84(2):269-281, 1997.
"Vitamin D
Inhibition of Prostate Adenocarcinoma Growth and Metastasis in the
Dunning Rat Prostate Model System." Getzenberg RH, Light BW,
Lapco PI, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day
RS, Trump DL, Johnson CS. Urology, 50(6):999-1006,
1997.
"Using multiple
decrement models to estimate risk and morbidity from specific AIDS
illnesses. Multicenter AIDS Cohort Study (MACS)." Hoover DR.
Peng Y. Saah AJ. Detels RR. Day RS. Phair JP. Statistics in Medicine,
15(21-22):2307-21; discussion 2337-40, 1996.
"Chemotherapy
in Non-Small Cell Lung Cancer: Pacitaxel/Carboplatin/Radiotherapy
in Regionally Avanced Diseases." Belani CP, Aisner J, Bahri
S, Jett J, Day R, Capazolli MJ, Hiponia D, Engstrom C. Seminars
in Oncology, 23(6 Suppl 16):113-116, 1996.
"The role
of immunological effector-cells in the development of posttransplant
lymphoproliferative disorders (PTLD)." Shpilberg O, Wilson
J, Green M, Nalesnik M, Day R, Herberman RB, Whiteside T.
Blood, 86(10)[1]:1354, 1995.
"Incorporating
toxicity considerations into the design of two-stage phase II clinical
trials." Bryant J, Day R. Biometrics, 51:1372-1383,
1995.
"An application
of decision theory to patient screening for an autologous tumor
vaccine trial." Shannon WD, Bryant J, Logan TF, Day R. Statistics
in Medicine, 14:2099-2110, 1995.
"Phase II
trial of oral 1,25-dihydroxyvitamin d (calcitriol) in hormone refractory
prostate cancer." Osborn JL, Schwartz GG, Smith DC, Bahnson
R, Day R, Trump DL. Urologic Oncology, 1:195-198, 1995.
"Treatment
of heaptic-metastatic colorectal cancer with a chemotherapeutic
emulsion: interim results of a phase I trial." Rubin
JT, Lotze MT, Rosenfelder D, Brumfield A, Howells R, Schwartz R,
Sylvestri S, Sammon J, Bron K, Orens P, Zajko A, Swanson D, Day
R. Annals of Surgical Oncology, 2:351-359, 1995.
"Calculation
of lytic units for the expression of cell mediated cytotoxicities."
Bryant J, Day R, Whiteside T, Herberman R. J Immuno Methods,
146:91-103, 1992.
"The selective
use of amsa following high-dose cytarabine in patients with acute
myeloid leukaemia in relapse." Larson RA, Day RS, Axarnia N,
Bennett JM, Browman G, Goldberg J, Gottlieb A, Grunwald H, Miller
K, Raza A, Vogler R, Winto E, Preisler H. Brit J Hema., 82:337-346,
1992.
"Immunological
effects of treatment with sequential administration of recombinant
interferon gamma and alpha in patients with metastatic renal cell
carcinoma during a phase I trial." Ernstoff MS, Gooding W,
Nair S, Bahnson RR, Miketic LM, Banner B, Day R, Whiteside TL, Titus-Ernstoff
L, Kirkwood JM. Cancer Research, 52:91-103, 1992.
"Cold ischemia
time versus outcome of human liver transplantation using UW solution."
Furukawa H, Todo S, Imventarza O, Wu M, Day R, and Starzl TE.
Transplant Proc., 23:1550-1551, 1991.
"Preliminary
Trial of Nonrecombinant Interferon Alpha in Recurrent Squamous Cell
Carcinoma of the Head and Neck." Vlock DR, Johnson J, Myers
E, Day R, Gooding WE, Whiteside T, Pelch K, Sigler B, Wagner R,
Colao D, et al. Head and Neck, 13(1):15-21, 1991.
"Empirical
Bayes analysis for systems of mixed models with linked autocorrelated
random effects." Bryant J, Day R. Amer Stat Assoc.,
86:1007-1012, 1991.
"Gene Amplification
and gene dosage in cell lines derived from squamous cell carcinoma
of the head and neck." Yin X, Donovan-Peluso M, Whiteside T,
Johnson J, Day R, Herberman R, Locker J.Genes, Chromosomes &
Cancer,3:443-454, 1991.
"Natural killer
(NK) cytotoxicity in diagnosis of immune dysfunction: criteria for
a reproducible assay." Whiteside T, Bryant J, Day R, Herberman
R. Journal of Clinical Laboratory Analysis, 4:102-114,
1990.
"Evaluation
of tetrazolium-based semi-automatic colorimetric assay for measurement
of antitumor cytotoxicity." Heo DS, Park J-G, Hata K, Day R,
Herberman R, Whiteside T. Cancer Research, 50:3681-3690,
1990.
"Direct relationship
between Remission duration in acute myeloid leukemia and cell cycle
kinetics." Raza A, Preisler H, Day R, Yasin Z, White M, Lykins
J, Kukla C, Barcos M, Bennett J, Browman G, Browman G, Goldberg
J, Grunwald H, Larson R, Vardiman J, Vogler R. Blood,
76 (11): 2791-7, 1990.
"MDR1 transcript
levels as an indication of resistant disease in acute nonlymphocytic
leukemia." Preisler HD, Gottesman M, Raza A, Pastan I, Day
R. Br. J. Haematol, 75:340-345, 1990.
"MDR1 Transcript
Levels As An Indicator of Resistant Disease in Acute Myelogenous
Leukaemia." Sato H, Preisler H, Day R, Raza A, Larson R, Browman
G., Goldberg J, Vogler R, Grunwald H, Gottlieb A, et al.
British Journal of Haematology, 75(3):340-345, 1990.
"A phase IA
trial of the combination of recombinant interferons gamma and alpha
in patients with metastatic renal cell carcinoma. " Ernstoff
M, Gooding W, Nair S, Bahnson R, Miketic L, Banner B, Day R, Titus-Ernstoff
J. Clin. Invest., 8(10):1637-49, 1990.
"Investigation
of a potential cancer cluster in Randolph, Massachusetts."
Day R., Ware J., Wartenberg D, Zelen M. Journal of Clinical
Epidemiology, 42:137-150, 1988.
"A multitype
branching model for heterogeneous cell populations." Day R.
Math BioSciences, 78:73-80, 1986.
"Treatment
sequencing, asymmetry, and uncertainty: new strategies for combining
cancer treatments." Day R. Cancer Res, 46:3886-3887,
1986.
"Chemotherapy
for metastatic non-small cell bronchogenic carcinoma: Cyclophosphamide,
doxorubicin, and etoposide versus mitomycin and vinblastine
(EST 2575, Generation IV)." Ruckdeschel JC, Day R, Weissman
CH, Stolback LL, Creech RH. Canc TR Rep., 68:1325-1329,
1984.
"Improved
echocardiographic visualization in emphysematous subjects."
Cohen J, Anwar KN, Day R. J Med Soc NJ, 90:815-181,
1983.
"A randomized
phase II study of meta-AMSA and neocarzinostatin in non-small bronchogenic
carcinoma." Ettinger DS, Day R, Ferrard JA, Ruckdeschel JC,
Woll JE, Creech RH, Vogl SE. Am J Clin Onc.,
167-170, 1983.
Contact Information
Sterling Plaza
201 North Craig Street, Suite 325
Pittsburgh, PA 15213
Telephone: 412-383-1573
Facsimile: 412-383-1535
Email: day@upci.pitt.edu
|
 |
